Trial
NCT04513548
Study of Mechanism of Action of Ligelizumab (QGE031) in Patients With Chronic Urticaria
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Novartis Pharmaceuticals
Collaborators
—
Condition
Chronic Spontaneous Urticaria
Intervention
Ligelizumab
Why stopped
Company decision
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-06-18